LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

CEL-SCI Corp

Chiusa

SettoreSettore sanitario

0.22

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

0.22

Massimo

0.22

Metriche Chiave

By Trading Economics

Entrata

-964K

-7.1M

EPS

-0.096

EBITDA

-225K

-5.9M

Dividendi

By Dow Jones

Utili prossimi

14 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-23M

21M

Apertura precedente

0.22

Chiusura precedente

0.22

Notizie sul Sentiment di mercato

By Acuity

86%

14%

363 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

CEL-SCI Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

16 mag 2025, 19:39 UTC

I principali Market Mover

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

17 mag 2025, 09:30 UTC

Notizie principali
Utili

In a Trade War, Walmart Lacks Some of Amazon's Ammunition -- Heard on the Street -- WSJ

17 mag 2025, 08:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

17 mag 2025, 08:20 UTC

Discorsi di Mercato
Utili

Financial Services Roundup: Market Talk

16 mag 2025, 23:18 UTC

Notizie principali

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16 mag 2025, 22:30 UTC

Notizie principali

U.S. Loses Last Triple-A Credit Rating -- Update

16 mag 2025, 21:56 UTC

Discorsi di Mercato

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16 mag 2025, 21:56 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

16 mag 2025, 21:54 UTC

Notizie principali

U.S. Loses Last Triple-A Credit Rating -- WSJ

16 mag 2025, 21:22 UTC

Discorsi di Mercato

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16 mag 2025, 21:17 UTC

Discorsi di Mercato

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16 mag 2025, 21:17 UTC

Notizie principali

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16 mag 2025, 21:05 UTC

Discorsi di Mercato

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16 mag 2025, 20:55 UTC

Acquisizioni, Fusioni, Takeovers

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 mag 2025, 20:50 UTC

Discorsi di Mercato
Utili

Financial Services Roundup: Market Talk

16 mag 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

16 mag 2025, 20:37 UTC

Notizie principali

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16 mag 2025, 20:33 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16 mag 2025, 20:30 UTC

Acquisizioni, Fusioni, Takeovers

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16 mag 2025, 20:18 UTC

Notizie principali

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16 mag 2025, 20:16 UTC

Notizie principali

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16 mag 2025, 20:15 UTC

Utili

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16 mag 2025, 20:11 UTC

Acquisizioni, Fusioni, Takeovers

Henry Schein: William K. Daniel Joins Board

16 mag 2025, 20:10 UTC

Acquisizioni, Fusioni, Takeovers

Henry Schein: Strategic Investment by KKR Completed

16 mag 2025, 20:05 UTC

Acquisizioni, Fusioni, Takeovers

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 mag 2025, 19:38 UTC

Discorsi di Mercato

Oil Futures Post Second Straight Weekly Gain -- Market Talk

16 mag 2025, 19:07 UTC

Discorsi di Mercato

U.S. Natural Gas Futures End Week Lower -- Market Talk

16 mag 2025, 18:51 UTC

Notizie principali

Early Read on Consumer Sentiment Falls to Second Lowest on Record -- 5th Update

16 mag 2025, 18:41 UTC

Acquisizioni, Fusioni, Takeovers

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 mag 2025, 18:37 UTC

Discorsi di Mercato

Gold Futures End Week on Negative Note -- Market Talk

Confronto tra pari

Modifica del prezzo

CEL-SCI Corp Previsione

Consenso sulla valutazione

By TipRanks

0 ratings

0

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

N/A / 0.2494Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

363 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo CEL-SCI Corp

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.